Authors: Ma. Vinna N. Crisostomo, MD, Mary Jo Kristine S. Bunagan, MD, FPDS
A 23-year-old male diagnosed with Hansen’s disease, BBBL, was started on multi-drug therapy (MDT). On his 6th month of therapy, he was started on prednisone 40mg/day for management of type 2 lepra reaction. The dose
of prednisone was decreased by 5 mg every two weeks. On the 12th month of therapy, the dose of prednisone was decreased to 10 mg/day. However, the presence of new generalized papules associated with fever and arthralgia was noted. As an attending physician, one would want to add a steroid-sparing
agent together with prednisone that would help control the lepra reaction of this patient to prevent the consequences of long-term steroid therapy
Crisostomo MV, Bunagan MJ. A critical appraisal of an article on therapy: Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions: an assessor-blinded, randomized controlled clinical trial. J Phil dermatol Soc. 2018; 27(1): 87-9.
Hanses, Disease, BBBL, Fusidic Acid
1. Panghi D and Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol and Leprol 2013;79(6)736-749.
2. Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. Anais Brasileiros de Dermatologia 2008; 83(1):75-82.
3. World Health Organization. WHO expert committee on leprosy: eighth report. Geneva.2010.
4. Franzblau SG, Chan GP, Garcia-Ignacio et al. Clinical trial of fusidic acid for lepromatous leprosy. Antimicrob Agents Chemother 1994; 38(7):1651-4.
5. Gabriel MT, Hipolito RH, Chan GP, Salvador LR et al. Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions:
Authors: Katrina Carmela M. Belen, MD, DPDS, Jasmin J.Jamora, MD, FPDS , Ma. Cecilia P. Ingente MD, DPDSAbstractBackground: Dermoscopy, a non-invasive diagnostic tool, has been proven to improve the diagnostic accuracy of vascular tumors since it can aid in...
A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions
Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS Abstract Background: Virgin coconut oil (VCO) has been reported...
Primary Cutaneous Anaplastic Large Cell Lymphoma (PC-ALCL) is a rare Non-Hodgkin lymphoma (NHL) representing approximately 9% of all cutaneous lymphomas.3 It usually manifests as a slow-growing, solitary tumor which has a tendency to regress spontaneously. However, metastasis is reported in 5-10% of cases.